Date published: 2025-10-26

00800 4573 8000

SCBT Portrait Logo
Seach Input

SLC17A (solute carrier family 17) Inibidores

The SLC17A (solute carrier family 17) family comprises a group of membrane transport proteins that play key roles in the transport of a variety of substrates, including organic anions, phosphates, and neurotransmitters. Members of this family are primarily known as phosphate transporters (SLC17A1-4) and vesicular glutamate transporters (VGLUTs, SLC17A5-7). The phosphate transporters are involved in the renal reabsorption of phosphate, a critical process for maintaining phosphate homeostasis, bone mineralization, and overall metabolic function. The VGLUTs are crucial in the central nervous system, where they transport glutamate into synaptic vesicles, facilitating excitatory neurotransmission. The signaling and function of SLC17A transporters are essential in various physiological processes, from bone health to nerve communication, and their dysfunction is implicated in several diseases, including neurological disorders and phosphate metabolism abnormalities.

Targeting SLC17A signaling for disruption or inhibition with small molecules enables a more detailed understanding of the diverse roles these transporters play in physiological and pathological processes. By inhibiting specific SLC17A transporters, researchers can delineate their individual contributions to phosphate homeostasis and neurotransmitter regulation. Such targeted approaches are crucial in elucidating the mechanisms of diseases related to phosphate imbalance or glutamate signaling disorders. Additionally, the use of small molecule inhibitors can shed light on the potential targets within the SLC17A family for conditions like osteoporosis or neurodegenerative diseases.

VEJA TAMBÉM

Items 11 to 20 of 23 total

Mostrar:

Nome do ProdutoCAS #Numero de CatalogoQuantidadePrecoUso e aplicacaoNOTAS

Sofosbuvir

1190307-88-0sc-482362
25 mg
$143.00
1
(0)

Um inibidor da ecto-ATPase, potencialmente alterando os níveis de ATP extracelular, afectando indiretamente o SLC17A.

FCCP

370-86-5sc-203578
sc-203578A
10 mg
50 mg
$92.00
$348.00
46
(1)

Um protonóforo, perturba os gradientes de protões, influenciando potencialmente a função SLC17A.

Niflumic acid

4394-00-7sc-204820
5 g
$31.00
3
(1)

Um medicamento anti-inflamatório não esteroide, pode afetar indiretamente os canais iónicos e os transportadores como o SLC17A.

Probenecid

57-66-9sc-202773
sc-202773A
sc-202773B
sc-202773C
1 g
5 g
25 g
100 g
$27.00
$38.00
$98.00
$272.00
28
(2)

Inibe de forma competitiva vários transportadores de aniões, reduzindo potencialmente a função dos membros da família SLC17.

Phloridzin dihydrate

7061-54-3sc-215708
sc-215708A
250 mg
1 g
$48.00
$117.00
(0)

Inibe os transportadores dependentes de sódio, podendo reduzir a absorção competitiva de fosfato.

Suramin sodium

129-46-4sc-507209
sc-507209F
sc-507209A
sc-507209B
sc-507209C
sc-507209D
sc-507209E
50 mg
100 mg
250 mg
1 g
10 g
25 g
50 g
$149.00
$210.00
$714.00
$2550.00
$10750.00
$21410.00
$40290.00
5
(1)

Inibe de forma não selectiva várias proteínas de membrana, possivelmente alterando o transporte relacionado com o SLC17A.

Indomethacin

53-86-1sc-200503
sc-200503A
1 g
5 g
$28.00
$37.00
18
(1)

Inibe indiretamente os transportadores de aniões ao afetar a síntese de prostaglandinas, alterando a dinâmica do transporte renal.

Furosemide

54-31-9sc-203961
50 mg
$40.00
(1)

Um diurético de alça que inibe o NKCC2, pode ter efeitos secundários no transporte de fosfato.

Bumetanide (Ro 10-6338)

28395-03-1sc-200727
sc-200727A
1 g
5 g
$107.00
$224.00
9
(1)

À semelhança da furosemida, inibe a NKCC2, o que pode influenciar indiretamente a atividade da SLC17A.

Lithium

7439-93-2sc-252954
50 g
$214.00
(0)

Afecta a inositol monofosfatase levando a alterações no transporte de aniões, podendo alterar a função SLC17A.